Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Operating Expenses: 2010-2025

Historic Other Operating Expenses for Iovance Biotherapeutics (IOVA) over the last 5 years, with Sep 2025 value amounting to $47.5 million.

  • Iovance Biotherapeutics' Other Operating Expenses rose 15.12% to $47.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $194.0 million, marking a year-over-year increase of 130.26%. This contributed to the annual value of $124.0 million for FY2024, which is 1052.91% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Other Operating Expenses stood at $47.5 million, which was down 16.20% from $56.7 million recorded in Q2 2025.
  • Iovance Biotherapeutics' Other Operating Expenses' 5-year high stood at $56.7 million during Q2 2025, with a 5-year trough of $2.0 million in Q2 2023.
  • For the 3-year period, Iovance Biotherapeutics' Other Operating Expenses averaged around $28.5 million, with its median value being $35.7 million (2024).
  • Data for Iovance Biotherapeutics' Other Operating Expenses shows a peak YoY surged of 1,430.15% (in 2024) over the last 5 years.
  • Over the past 3 years, Iovance Biotherapeutics' Other Operating Expenses (Quarterly) stood at $4.4 million in 2023, then soared by 818.35% to $40.1 million in 2024, then grew by 15.12% to $47.5 million in 2025.
  • Its Other Operating Expenses was $47.5 million in Q3 2025, compared to $56.7 million in Q2 2025 and $49.7 million in Q1 2025.